bluebird bio to Present at Deutsche Bank BioFEST Conference

  bluebird bio to Present at Deutsche Bank BioFEST Conference

2013 Deutsche Bank BioFEST Conference

Business Wire

CAMBRIDGE, Mass. -- November 27, 2013

bluebird bio, Inc. (Nasdaq:BLUE) announces that management will present at the
Deutsche Bank BioFEST Conference to be held December 2 - 3, 2013 at the Four
Seasons Hotel, Boston, MA. Nick Leschly, Chief bluebird, will provide an
overview of the company at the conference on Monday, December 2, 2013 at 11:20
AM (ET).

To access a simultaneous webcast of Mr. Leschly's overview via the internet,
log on to the "Calendar of Events" section on the Investor and Media page of
the bluebird bio's website at http://investor.bluebirdbio.com. Please connect
to the website at least ten minutes prior to the start of the presentation to
ensure adequate time for a reliable connection and any software download that
may be necessary for the webcast.

A replay of the webcasts will be available on bluebird bio's website for
ninety days following the conference. The investor presentation will be
available for download in PDF format immediately following the presentation in
the "Calendar of Events" section of the Investor and Media page of the
bluebird bio's website at http://investor.bluebirdbio.com.

About bluebird bio, Inc.

bluebird bio is a clinical-stage company committed to developing potentially
transformative gene therapies for severe genetic and orphan diseases. bluebird
bio has two clinical-stage programs in development. The most advanced product
candidate, Lenti-D, is in a recently-initiated phase 2/3 study for the
treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare,
hereditary neurological disorder affecting young boys. The next most advanced
product candidate, LentiGlobin, is currently in a phase 1/2 study in France
for the treatment of beta-thalassemia major and severe sickle cell disease. A
second phase 1/2 study with LentiGlobin in the United States has been
initiated for the treatment of beta-thalassemia major.

bluebird bio also has an early-stage chimeric antigen receptor-modified T cell
(CAR-T) program for oncology in partnership with Celgene Corporation.

bluebird bio has operations in Cambridge, Massachusetts and Paris, France. For
more information, please visit www.bluebirdbio.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
regarding the advancement of the Company’s clinical studies, the timing of
data announcement and the potential safety and clinical benefits of the
Company’s product candidates. Any forward-looking statements in this press
release are based on management's current expectations of future events and
are subject to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in or implied
by such forward-looking statements. These risks and uncertainties include, but
are not limited to, the risk of cessation or delay of any of the ongoing or
planned clinical studies and/or our development of our product candidates, the
risk of a delay in the enrollment of patients in the Company’s clinical
studies, the risk that the results of previously conducted studies involving
similar product candidates will not be repeated or observed in ongoing or
future studies involving current product candidates, the risk that our
collaboration with Celgene will not continue or will not be successful, and
the risk that any one or more of our product candidates will not be
successfully developed and commercialized. For a discussion of other risks and
uncertainties, and other important factors, any of which could cause our
actual results to differ from those contained in the forward-looking
statements, see the section entitled "Risk Factors" in our quarterly report on
Form 10-Q, as well as discussions of potential risks, uncertainties, and other
important factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date of the
release, and bluebird bio undertakes no duty to update this information unless
required by law.

Contact:

Investor Relations:
bluebird bio, Inc.
Richard E. T. Smith, Ph.D.
617-588-3321
or
Media:
Pure Communications, Inc.
Dan Budwick
973-271-6085
 
Press spacebar to pause and continue. Press esc to stop.